I am an independent HEOR and Market Access consultant with over 20 years of experience helping pharmaceutical and biotech organisations navigate the critical path from innovation to patient access.

Throughout my career, I have worked at the interface of evidence strategy, HTA and commercial decision-making, translating complex clinical, economic and patient-reported data into clear, credible value narratives that support reimbursement and access.

My background includes senior leadership roles, where I built and led HEOR teams across Europe and established markets, followed by independent consultancy and interim leadership roles with global pharma and biotech organisations.

I specialise in global HEOR, market access strategy and HTA readiness, integrated evidence generation, COA/PRO strategy and fractional HEOR leadership. Clients value my ability to combine strategic perspective with hands-on delivery, particularly in time-critical and evidence-sensitive environments.

I work closely with leadership teams, clinical development, regulatory, market access, medical affairs and HEOR colleagues to shape evidence strategies that stand up to scrutiny and drive meaningful access outcomes.

At the heart of my work is a commitment to scientific rigour, trusted partnership and ensuring that innovation translates into real patient benefit.